Stormorken Astrid T, Bowitz-Lothe Inger Marie, Norèn Tove, Kure Elin, Aase Steinar, Wijnen Juul, Apold Jaran, Heimdal Ketil, Møller Pål
Section of Genetic Counselling, Department of Cancer Genetics, The Norwegian Radium Hospital, N-0310 Oslo, Norway.
J Clin Oncol. 2005 Jul 20;23(21):4705-12. doi: 10.1200/JCO.2005.05.180.
Hereditary nonpolyposis colorectal cancer (HNPCC) may be caused by mutations in mismatch repair (MMR) genes. The aim of this study was to validate immunohistochemistry and family history as prescreening tools to predict germline mutations in MLH1, MSH2, and MSH6.
Pedigrees from 250 families were extended, cancer diagnoses were verified, and families were classified according to the Amsterdam and the Bethesda criteria. Tumor specimens were examined with immunohistochemistry for the presence of MLH1, MSH2, and MSH6 proteins. Mutation analyses were performed in blood samples from the same patients.
Blood samples from affected index persons in 181 families and tumor specimens from 127 of the affected index persons were obtained. Thirty tumors lacked one or more gene products. Sensitivity of immunohistochemistry to detect mutation carriers was 100%, specificity was 82%, and positive predictive value was 85%. Sensitivities, specificities, and positive predictive values for the Amsterdam criteria were 82%, 8%, and 45%, respectively, and for the Bethesda criteria were 100%, 0%, and 48%, respectively. Distribution of mutations was MLH1 = 4, MSH2 = 11, and MSH6 = 4.
Wide clinical criteria to select HNPCC kindreds, followed by immunohistochemistry of tumor material from one affected person in each family, had high sensitivity and specificity to predict MMR mutations.
遗传性非息肉病性结直肠癌(HNPCC)可能由错配修复(MMR)基因突变引起。本研究的目的是验证免疫组织化学和家族史作为预筛查工具,以预测MLH1、MSH2和MSH6基因的种系突变。
扩展了250个家族的谱系,核实癌症诊断,并根据阿姆斯特丹标准和贝塞斯达标准对家族进行分类。用免疫组织化学检查肿瘤标本中MLH1、MSH2和MSH6蛋白的存在情况。对同一患者的血样进行突变分析。
获取了181个家族中受影响索引患者的血样以及127名受影响索引患者的肿瘤标本。30个肿瘤缺乏一种或多种基因产物。免疫组织化学检测突变携带者的敏感性为100%,特异性为82%,阳性预测值为85%。阿姆斯特丹标准的敏感性、特异性和阳性预测值分别为82%、8%和45%,贝塞斯达标准的敏感性、特异性和阳性预测值分别为100%、0%和48%。突变分布为MLH1 = 4,MSH2 = 11,MSH6 = 4。
采用广泛的临床标准选择HNPCC家族,随后对每个家族中一名受影响者的肿瘤材料进行免疫组织化学检测,对预测MMR突变具有高敏感性和特异性。